PE20191648A1 - Nuevos receptores de celulas t y terapia inmunologica que los utiliza - Google Patents
Nuevos receptores de celulas t y terapia inmunologica que los utilizaInfo
- Publication number
- PE20191648A1 PE20191648A1 PE2019001076A PE2019001076A PE20191648A1 PE 20191648 A1 PE20191648 A1 PE 20191648A1 PE 2019001076 A PE2019001076 A PE 2019001076A PE 2019001076 A PE2019001076 A PE 2019001076A PE 20191648 A1 PE20191648 A1 PE 20191648A1
- Authority
- PE
- Peru
- Prior art keywords
- antigen recognition
- construct
- seq
- fragment
- derivative
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Abstract
Referido a una construccion de reconocimiento de antigeno que comprende por lo menos una region determinante de complementariedad (CDR) 3 que contiene por lo menos 80% de identidad de secuencia, con una secuencia de aminoacidos que se selecciona de las SEQ ID NOs: 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, 81, 87, 93, 99, 105, 111 y 117. Dicha construccion de reconocimiento de antigeno es capaz de unirse especificamente y/o selectivamente a un peptido antigenico (MAGEA 1), preferiblemente un peptido de la SEQ ID NO: 133 a 142. En donde dicha construccion es un anticuerpo, un derivado o fragmento del mismo, o un receptor de celulas T (TCR) o un derivado o fragmento del mismo. Tambien se refiere a acidos nucleicos que codifican para las construcciones de reconocimiento de antigeno de la invencion, vectores que comprenden estos acidos nucleicos, celulas recombinantes que expresan las construcciones de reconocimiento de antigeno, composiciones farmaceuticas que comprenden dichos compuestos y su uso en diagnostico, tratamiento y prevencion de enfermedad proliferativa, como el cancer de celulas renales, c. gastrico, c. colorrectal, entre otros.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662431588P | 2016-12-08 | 2016-12-08 | |
DE102016123847.3A DE102016123847B3 (de) | 2016-12-08 | 2016-12-08 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
PCT/EP2017/081800 WO2018104438A1 (en) | 2016-12-08 | 2017-12-07 | Novel t cell receptors and immune therapy using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20191648A1 true PE20191648A1 (es) | 2019-11-07 |
Family
ID=61623755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019001076A PE20191648A1 (es) | 2016-12-08 | 2017-12-07 | Nuevos receptores de celulas t y terapia inmunologica que los utiliza |
Country Status (14)
Country | Link |
---|---|
US (1) | US10874731B2 (es) |
EP (1) | EP3551221B1 (es) |
KR (1) | KR20190088539A (es) |
CN (1) | CN110114085A (es) |
AU (2) | AU2017373740C1 (es) |
BR (1) | BR112019010972A2 (es) |
CA (1) | CA3045233C (es) |
CR (1) | CR20190278A (es) |
DE (1) | DE102016123847B3 (es) |
MA (1) | MA49236B1 (es) |
MX (1) | MX2019006724A (es) |
PE (1) | PE20191648A1 (es) |
TW (1) | TWI736719B (es) |
WO (1) | WO2018104438A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3551221T3 (pl) * | 2016-12-08 | 2022-02-28 | Immatics Biotechnologies Gmbh | Nowe receptory komórek t i immunoterapia z ich zastosowaniem |
DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
BR112019018863A8 (pt) * | 2017-03-15 | 2023-05-02 | Hutchinson Fred Cancer Res | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos |
EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
TW202102530A (zh) | 2019-04-04 | 2021-01-16 | 德商梅迪基因免疫治療公司 | 黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途 |
PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
US20220409711A1 (en) * | 2019-11-05 | 2022-12-29 | Board Of Regents, The University Of Texas System | Hla restricted hormad1 t cell receptors and uses thereof |
CN111208304B (zh) * | 2020-01-20 | 2023-06-16 | 中国医学科学院北京协和医院 | 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途 |
MX2022010461A (es) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas. |
WO2022040631A1 (en) * | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス,アイエヌシー. | Cd8ポリペプチド、組成物、及びそれらの使用方法 |
US20220356252A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
US20230310607A1 (en) | 2021-11-09 | 2023-10-05 | T-Knife Gmbh | Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits |
WO2023133296A2 (en) * | 2022-01-07 | 2023-07-13 | Sorrento Therapeutics, Inc. | Engineered pd-l1-targeting gamma delta t cell receptors |
WO2023175069A1 (en) * | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library for pramevld tcrs |
WO2023175070A1 (en) * | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library |
WO2023179795A1 (zh) * | 2022-03-25 | 2023-09-28 | 立凌生物制药(苏州)有限公司 | 一种快速且简便地获得正确配对tcr的方法以及获得的tcr |
WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
CN116970066B (zh) * | 2023-09-19 | 2024-03-12 | 恒瑞源正(广州)生物科技有限公司 | Mage-a1特异性t细胞受体及其用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
CA2848209C (en) | 2011-09-15 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
EP3747899A3 (en) | 2013-01-29 | 2021-02-24 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | High avidity binding molecules recognizing mage-a1 |
KR102301464B1 (ko) * | 2013-06-10 | 2021-09-14 | 다나-파버 캔서 인스티튜트 인크. | 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물 |
US10202640B2 (en) | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
WO2016011210A2 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
CN105316362B (zh) * | 2015-08-19 | 2020-03-17 | 暨南大学 | 一种Dual-RMCE介导的TCR基因置换***及其方法 |
GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
CN106749620B (zh) * | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
ES2949342T3 (es) | 2016-06-17 | 2023-09-27 | Medigene Immunotherapies Gmbh | Receptores de células T y usos de los mismos |
PL3551221T3 (pl) * | 2016-12-08 | 2022-02-28 | Immatics Biotechnologies Gmbh | Nowe receptory komórek t i immunoterapia z ich zastosowaniem |
DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
BR112019018863A8 (pt) | 2017-03-15 | 2023-05-02 | Hutchinson Fred Cancer Res | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos |
JP7391015B2 (ja) | 2017-09-29 | 2023-12-04 | アメリカ合衆国 | P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法 |
-
2016
- 2016-12-08 DE DE102016123847.3A patent/DE102016123847B3/de active Active
-
2017
- 2017-12-07 MX MX2019006724A patent/MX2019006724A/es unknown
- 2017-12-07 PE PE2019001076A patent/PE20191648A1/es unknown
- 2017-12-07 WO PCT/EP2017/081800 patent/WO2018104438A1/en unknown
- 2017-12-07 KR KR1020197019005A patent/KR20190088539A/ko not_active IP Right Cessation
- 2017-12-07 CR CR20190278A patent/CR20190278A/es unknown
- 2017-12-07 MA MA49236A patent/MA49236B1/fr unknown
- 2017-12-07 BR BR112019010972A patent/BR112019010972A2/pt unknown
- 2017-12-07 US US15/834,633 patent/US10874731B2/en active Active
- 2017-12-07 EP EP17829609.1A patent/EP3551221B1/en active Active
- 2017-12-07 CA CA3045233A patent/CA3045233C/en active Active
- 2017-12-07 CN CN201780075284.2A patent/CN110114085A/zh active Pending
- 2017-12-07 AU AU2017373740A patent/AU2017373740C1/en active Active
- 2017-12-08 TW TW106143114A patent/TWI736719B/zh active
-
2021
- 2021-05-14 AU AU2021203099A patent/AU2021203099A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017373740B2 (en) | 2021-03-18 |
CN110114085A (zh) | 2019-08-09 |
EP3551221A1 (en) | 2019-10-16 |
US10874731B2 (en) | 2020-12-29 |
MX2019006724A (es) | 2019-08-22 |
AU2021203099A1 (en) | 2021-06-10 |
TW201827458A (zh) | 2018-08-01 |
KR20190088539A (ko) | 2019-07-26 |
CA3045233A1 (en) | 2018-06-14 |
EP3551221B1 (en) | 2021-11-10 |
US20180161396A1 (en) | 2018-06-14 |
MA49236B1 (fr) | 2022-02-28 |
TWI736719B (zh) | 2021-08-21 |
BR112019010972A2 (pt) | 2019-10-15 |
CA3045233C (en) | 2023-11-28 |
MA49236A (fr) | 2020-04-15 |
WO2018104438A1 (en) | 2018-06-14 |
DE102016123847B3 (de) | 2018-04-05 |
CR20190278A (es) | 2019-11-19 |
AU2017373740C1 (en) | 2021-08-26 |
AU2017373740A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
CL2020001181A1 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos. | |
CY1124997T1 (el) | Καινοτομοι υποδοχεις τ-κυτταρων και ανοσοθεραπεια με την χρηση των ιδιων | |
CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
CR20190095A (es) | Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos | |
PE20180693A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer epitelial de ovario y otros tipos de cancer | |
PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
AR112604A1 (es) | Receptores de células t, e inmunoterapia usando los mismos | |
EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
PE20191248A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
PE20231014A1 (es) | Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres | |
AR124455A2 (es) | Proteínas de unión específicas y sus usos | |
PE20191404A1 (es) | Proteinas de union al receptor de glucagon y metodos para usarlas | |
PE20191617A1 (es) | Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer | |
EA202090712A1 (ru) | Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием | |
AR110504A1 (es) | Receptores de células t y terapia inmunológica que los utiliza | |
CY1124826T1 (el) | Υποδοχεις τ-κυτταρων και ανοσοθεραπεια με τη χρηση των ιδιων | |
CO2019006926A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
AR109345A1 (es) | Receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
AR113834A1 (es) | Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos | |
EA201990488A1 (ru) | Новые t-клеточные рецепторы и иммунотерапия с их применением | |
AR110682A1 (es) | Receptores de células t y terapia inmunológica que los utiliza |